Craft

Advanced
Cipla

Cipla Operating Metrics

Header placeholder lorem ipsum dolor sit amet, consectetur adipiscing elit.
Button CTA
banner
Cipla key operating metrics including Markets, environmental, and social and governance score (ESG).

Markets

78
8.2%

FY, 2024

Drug Master Files Filed (Emerging Markets)

426
3.9%

FY, 2024

Drug Master Files Filed (India)

3
25.0%

FY, 2024

Operating Metrics

MetricsFY, 2022FY, 2023FY, 2024
Markets868578
Drug Master Files Filed (Emerging Markets)544410426
Drug Master Files Filed (India)243
Drug Master Files Filed (Europe)161847
Drug Master Files Filed (South Africa and Global Access)6116
Drug Master Files Filed (United States)121519
Drug Master Files Filed583458503
Dossiers Filed (Australia and New Zealand)12
Dossiers Approved275270333
Dossiers Approved (Emerging Markets)87115111
Dossiers Approved (South Africa and Global Access)9711285
Dossiers Approved (Europe)4930120
Dossiers Approved (United States)1365
Dossiers Filed (South Africa and Global Access)19510072
Dossiers Filed (Europe)161414
Dossiers Filed (United States)121313
Dossiers Filed (India)381219
New Drug Application Portfolio (Tentatively Approved)121212
New Drug Application Portfolio (Approved)466
Dossiers Approved (Australia and New Zealand)7
Dossiers Approved (India)22712
Manufacturing Capacity (Lyophilised Injections)11.5M1.6M1.9M
Manufacturing Capacity (Oral Liquids)51.2M51.6M51.6M
Manufacturing Capacity (Aerosol pMDI)144.2M125.8M129.1M
Manufacturing Capacity (Respules)750M773.6M726.9M
Manufacturing Capacity (Nasal Sprays)50.6M48M43.2M
Manufacturing Capacity (Tablets and Capsules)32.7B30.5B28.3B
Products1.5K1.5K1.5K
Dosage Forms505050
Manufacturing Sites474746
Products Launched (Emerging Markets)152744
Products Launched (India)101214
Products Launched (Europe)202020
Products Launched (South Africa and Global Access)321010
Products Launched (United States)16913
Products Launched Yearly9378101
Therapeutic Categories656565
Dossiers Filed423270270
Dossiers Filed (Emerging Markets)150115151
Suppliers8.6K8.7K8.3K
Critical Suppliers (Tier 1)433597571
New Drug Application Portfolio (Under Approved)334
New Drug Application Portfolio192122
Abbreviated New Drug Application Portfolio (Under Approved)197177
Abbreviated New Drug Application Portfolio (Tentatively Approved)661920
Abbreviated New Drug Application Portfolio (Approved)165155158
Abbreviated New Drug Application Portfolio250245255
Abbreviated New Drug Applications Approved1275
Abbreviated New Drug Applications Filed111412
Drug Master Files Filed (Australia and New Zealand)3
Manufacturing Capacity (Form Fill Seal Eyedrops)2.5M2.5M700K
Clinical Trials Initiated2331
Molecules Evaluated5040
Drug Master Files Filed (China)2
Clinical Trials Completed10
Dossiers Filed (China)1

Environmental, Social and Governance (ESG)

Overall

50-59 out of 100

Community

Employees

Environment

Governance

Premium Content only available in Craft’s Intelligence Portal
Learn more

Source:CSRHub

Footer menu

Product

Solutions

Resources

Company

© Craft.co 2026
Share price data provided by IEX